About US
Contact us
-
Allergan activists, ready for 'disruptive action,' call for split, sale, executive changesAfter Allergan revealed Wednesday that a major pipeline prospect had flunked a phase 3 trial, analysts predicted activist investors demanding change would ratchet up pressure on the company’s executi2019/3/11
-
Name of Amazon-JPMorgan-Berkshire Hathaway joint venture announcedAmazon has announced its joint venture with Berkshire Hathaway and JPMorgan Chase will be named Haven. The company, which is headquartered in Boston with another office in New York, launched its webs2019/3/8
-
Beam Therapeutics raises $135m to advance CRISPR technologiesUS-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies. The company also intends2019/3/8
-
Celgene’s fedratinib gets FDA priority review for myelofibrosisCelgene has secured the US Food and Drug Administration (FDA) priority review status for the new drug application (NDA) of fedratinib to treat patients with myelofibrosis. Myelofibrosis is a serious2019/3/7
-
BeiGene and Ambrx form R&D alliance for new biologicsChina-based immuno-oncology drugs maker BeiGene and American biopharmaceutical firm Ambrx have formed a research and development (R&D) partnership to develop next-generation biologic drugs. The w2019/3/7
-
Vertex reports preliminary data for triple combination cystic fibrosis therapyBoston-based pharmaceutical company Vertex has published promising interim analysis from two Phase III studies of a triple combination therapy of VX-445, tezacaftor and ivacaftor for cystic fibrosis.2019/3/6
-
Scott Gottlieb resigns as FDA commissionerScott Gottlieb has announced his resignation from the position of commissioner of the US Food and Drug Administration (FDA). Gottlieb cited his weekly commute from Connecticut to Washington as his ma2019/3/6
-
Janssen secures FDA approval for new depression drug SHAREJohnson & Johnson subsidiary Janssen Pharmaceutical has obtained approval from the US Food and Drug Administration (FDA) for its Spravato (esketamine) nasal spray to treat adults with major depre2019/3/5
-
Pfizer licences type 1 diabetes therapy from AnTolRxPfizer has licensed an immunotherapy treatment intended to combat Type 1 diabetes from US-based biotechnology firm AnToIRx. To acquire the rights, Pfizer exercised an option under an existing agreeme2019/3/5
-
CEPI joins forces with CureVac for vaccine printing platformThe Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with German biopharmaceutical firm CureVac that is developing a transportable automated messenger RNA (mRNA) vaccine printing2019/3/4